SCHEMBL7370545

SCHEMBL7370545

c1cncc(Cc2ncn[nH]2)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.56
HRH4 Q9H3N8 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
MMP2 P08253 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
NCOR2 Q9Y618 1/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 2/20 0.43
CHRNA7 P36544 1/20 0.42
TBXAS1 P24557 2/20 0.41
CHRNB2 P17787 2/20 0.41
CHRNA4 P43681 2/20 0.41
CYP2A6 P11509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24769738 0.75 CYP1A2 (0.54) HRH4HRH3MMP2CYP11B1CYP11B2
SCHEMBL727185 0.74 CYP1A2 (0.62) HRH4HRH3MMP2CYP11B1CYP11B2
SCHEMBL6168636 0.74 TAAR1 (0.68) HRH4HRH3MMP2CYP11B1CYP11B2
SCHEMBL31688985 0.74 TAAR1 (0.68) HRH4HRH3MMP2CYP11B1CYP11B2
SCHEMBL8007687 0.71 MMP2 (0.47) CYP2C19HRH4HRH3MMP2CYP11B1
SCHEMBL30373538 0.69 CYP11B1 (0.56) HRH4HRH3MMP2CYP11B1CYP11B2
SCHEMBL18459206 0.69 CYP11B1 (0.60) HRH4HRH3CYP11B1CYP11B2CYP1A2
SCHEMBL25181727 0.69 CYP11B1 (0.56) HRH4HRH3MMP2CYP11B1CYP11B2
SCHEMBL18459207 0.69 CYP11B1 (0.56) HRH4HRH3MMP2CYP11B1CYP11B2
SCHEMBL14257669 0.69 CYP1A2 (0.56) HRH4HRH3MMP2CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6090828-A ARTHERIOSCLEROSIS REITZ DAVID B (US) 2000-07-18 US disclosed
US-5451593-A Method of using 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of a glaucoma disorder G. D. SEARLE & CO. (US) 1995-09-19 US disclosed
US-5451591-A Method of using 5-arylheteroarylalkyl-1,3 5-trisubstituted-1,24-triazole compounds for treatment of circulatory disorders G. D. SEARLE & CO. (US) 1995-09-19 US disclosed
US-5196537-A Angiotensin/II/ antagonists; hypotensive agents G. D. SEARLE & CO. (US) 1993-03-23 US disclosed
WO-1992016523-A1 5-ARYLHETEROARYLALKYL-1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1992-10-01 WO disclosed
EP-0504888-A1 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders G.D. Searle & Co. (US) 1992-09-23 EP disclosed